Plus Therapeutics announced on August 15, 2025, that it reported stockholders’ equity of $3 million as of June 30, 2025. This figure satisfies Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity.
This compliance follows a delist determination from Nasdaq on June 3, 2025, after the company no longer satisfied the Equity Rule as of March 31, 2025. The company had timely requested a hearing before the Nasdaq Hearings Panel.
On July 22, 2025, Nasdaq notified the company that the Panel granted its request for an extension to evidence compliance with the Equity Rule. The filing of the Form 10-Q for Q2 2025 confirmed the regained compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.